Harper Sean E

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
15
Insider Sells Sum
$29.3M

Insider Activity of Harper Sean E

The largest sale of all time was on 2015-04-22 and amounted to 56000 shares of Amgen Inc. for $9.61M.

Biography of Harper Sean E

No biography is available at this moment.

2018-07-16SaleAmgen Inc.
AMGN
EVP, Research & Development
3,050
0.0005%
$195.71$596,916-0.43%
2018-06-12SaleAmgen Inc.
AMGN
EVP, Research & Development
3,050
0.0005%
$184.27$562,024+4.88%
2018-05-14SaleAmgen Inc.
AMGN
EVP, Research & Development
3,050
0.0005%
$174.10$531,005+11.16%
2018-04-12SaleAmgen Inc.
AMGN
EVP, Research & Development
3,050
0.0005%
$172.68$526,674+14.37%
2018-03-16SaleAmgen Inc.
AMGN
EVP, Research & Development
3,050
0.0004%
$189.75$578,738+3.24%
2018-02-14SaleAmgen Inc.
AMGN
EVP, Research & Development
3,050
0.0004%
$174.18$531,249+7.55%
2018-01-16SaleAmgen Inc.
AMGN
EVP, Research & Development
3,050
0.0004%
$185.62$566,141+3.88%
2017-12-12SaleAmgen Inc.
AMGN
EVP, Research & Development
3,050
0.0004%
$176.83$539,332+7.84%
2017-11-13SaleAmgen Inc.
AMGN
EVP, Research & Development
3,050
0.0004%
$171.58$523,319+10.09%
2017-10-09SaleAmgen Inc.
AMGN
EVP, Research & Development
3,050
0.0004%
$185.95$567,148+0.17%
2016-04-29SaleAmgen Inc.
AMGN
EVP, Research & Development
43,750
0.0058%
$157.99$6.91M+3.48%
2015-04-22SaleAmgen Inc.
AMGN
EVP, Research & Development
56,000
0.0075%
$171.58$9.61M-6.9%
2014-08-05SaleAmgen Inc.
AMGN
EVP, Research & Development
28,000
0.0037%
$127.29$3.56M+25.21%
2013-05-02SaleAmgen Inc.
AMGN
EVP, Research & Development
8,000
0.0005%
$50.44$403,520+8.47%
2012-07-27SaleAmgen Inc.
AMGN
EVP, Research & Development
39,900
0.0051%
$82.33$3.29M+6.41%
Company
About Prismo.proNewsPrivacy PolicyTerms of ServiceContact Us
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.